Gilead Sciences, Inc. $GILD Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,280,740 shares of the biopharmaceutical company’s stock after selling 72,218 shares during the quarter. Gilead Sciences makes up about 1.0% of Skandinaviska Enskilda Banken AB publ’s investment portfolio, making the stock its 14th largest position. Skandinaviska Enskilda Banken AB publ’s holdings in Gilead Sciences were worth $253,196,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC lifted its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. Howard Hughes Medical Institute acquired a new stake in Gilead Sciences during the 2nd quarter valued at $30,000. Finally, MTM Investment Management LLC grew its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.1%

Shares of GILD stock opened at $154.98 on Tuesday. The firm’s 50-day simple moving average is $130.94 and its 200-day simple moving average is $122.68. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The firm has a market cap of $192.28 billion, a P/E ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is 46.68%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 288,891 shares of company stock worth $40,303,946 over the last ninety days. 0.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Citigroup boosted their price target on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Truist Financial boosted their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Mizuho raised their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Wolfe Research boosted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Finally, TD Cowen raised their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.